Novo Nordisk Foundation: Bernie Sanders is wrong

Bernie Sanders is a strong critic of Novo Nordisk’s prices in the US. But his figures are factually incorrect, according to the foundation which owns the pharmaceutical firm.
CEO of the Novo Nordisk Foundation, Mads Krogsgaard. | Photo: Keld Navntoft
CEO of the Novo Nordisk Foundation, Mads Krogsgaard. | Photo: Keld Navntoft
by RITZAU ‎

Bernie Sanders failed to see the full picture when he criticized Novo Nordisk’s pricing of Ozempic and Wegovy in the US, says Mads Krogsgaard, CEO of the Novo Nordisk Foundation, in Danish media TV2’s magazine Business Class. 

Already a subscriber?Log in here

Read the whole article

Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

With your free trial you get:

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
  • Must be at least 8 characters, including three of: Uppercase, lowercase, numbers, symbols
    Must contain at least 2 characters
    Must contain at least 2 characters

    Get full access for you and your coworkers

    Start a free company trial today

    Share article

    Sign up for our newsletter

    Stay ahead of development by receiving our newsletter on the latest sector knowledge.

    Newsletter terms

    Front page now

    Photo: Mike Blake/Reuters/Ritzau Scanpix

    Gilead Sciences CMO to leave early 2025

    For subscribers

    Further reading